Morich Frank has made a significant move by acquiring 15,000 shares of Perspective Therapeutics, Inc. This transaction, reported on November 16, 2026, is noteworthy as it reflects Frank's confidence in the pharmaceutical preparations sector.
The acquisition was executed on November 12, 2026, at a price of $0.9971 per share, which translates to approximately EUR 0.90 per share, as noted in the filing. The transaction showcases Frank's direct ownership of the shares, which now totals 15,000 shares following this acquisition.
Background
Morich Frank is a private entity involved in the life sciences sector. The company has been active in the market, with a series of recent filings indicating ongoing engagement with Perspective Therapeutics, Inc. Perspective Therapeutics, based in Seattle, WA, is classified under the SIC code for pharmaceutical preparations [2834]. This classification highlights its role in developing and providing pharmaceutical products.
What the Filing Says
The filing details the acquisition of shares, stating, "The purchase was made in euros at a price of EUR 0.90 per share." This indicates a strategic investment by Frank, who is a director at Perspective Therapeutics.
Impact
This acquisition may impact various stakeholders, particularly within the pharmaceutical industry. As a director, Frank's investment could influence the company's strategic direction and investor sentiment.
What's Next
The filing does not say what happens next.
Read Next
CION Investment Corp partners with BC Partners for acquisition
Spangler acquires 2,006 shares of Brady Corp stock
Robinson Scott J. acquires shares in Brady Corp as director
Primo Brands Corp to Offer $700 Million in Senior Notes
Air Industries Group to Vote on Tenax Merger November 18
SunPower Inc. announces 1-for-35 reverse stock split







